Ascentage Pharma's Novel Bcl-2 Inhibitor Lisaftoclax Receives Approval from China's NMPA for Treatment of CLL/SLL Patients

Reuters

07/10

<a href="https://laohu8.com/S/AAPG">Ascentage Pharma</a>'s Novel Bcl-2 Inhibitor Lisaftoclax Receives Approval from China's NMPA for Treatment of CLL/SLL Patients

Ascentage Pharma Group International has announced that its novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), has received approval from China's National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously undergone at least one systemic therapy, including Bruton's tyrosine kinase $(BTK.AU)$ inhibitors. This marks lisaftoclax as the first Bcl-2 inhibitor to receive conditional approval and marketing authorization for CLL/SLL treatment in China, and the second such inhibitor approved globally. Developed by Ascentage Pharma, lisaftoclax aims to restore the normal apoptosis process in cancer cells by selectively blocking the antiapoptotic protein Bcl-2. The approval is based on positive results from a pivotal registrational Phase II study, highlighting Ascentage Pharma's capabilities in global clinical development and innovation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief on July 10, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2550612672"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550612672\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550612672?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-10 16:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550612672","market":"fut","top_or_hot":-1,"title":"Ascentage Pharma's Novel Bcl-2 Inhibitor Lisaftoclax Receives Approval from China's NMPA for Treatment of CLL/SLL Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AAPG\">Ascentage Pharma</a>'s Novel Bcl-2 Inhibitor Lisaftoclax Receives Approval from China's NMPA for Treatment of CLL/SLL Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ASPHF\">Ascentage Pharma</a> Group International has announced that its novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), has received approval from China's National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously undergone at least one systemic therapy, including Bruton's tyrosine kinase <a href=\"https://laohu8.com/S/BTK.AU\">$(BTK.AU)$</a> inhibitors. This marks lisaftoclax as the first Bcl-2 inhibitor to receive conditional approval and marketing authorization for CLL/SLL treatment in China, and the second such inhibitor approved globally. Developed by Ascentage Pharma, lisaftoclax aims to restore the normal apoptosis process in cancer cells by selectively blocking the antiapoptotic protein Bcl-2. The approval is based on positive results from a pivotal registrational Phase II study, highlighting Ascentage Pharma's capabilities in global clinical development and innovation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief on July 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascentage Pharma's Novel Bcl-2 Inhibitor Lisaftoclax Receives Approval from China's NMPA for Treatment of CLL/SLL Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscentage Pharma's Novel Bcl-2 Inhibitor Lisaftoclax Receives Approval from China's NMPA for Treatment of CLL/SLL Patients\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-10 16:57</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AAPG\">Ascentage Pharma</a>'s Novel Bcl-2 Inhibitor Lisaftoclax Receives Approval from China's NMPA for Treatment of CLL/SLL Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ASPHF\">Ascentage Pharma</a> Group International has announced that its novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), has received approval from China's National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously undergone at least one systemic therapy, including Bruton's tyrosine kinase <a href=\"https://laohu8.com/S/BTK.AU\">$(BTK.AU)$</a> inhibitors. This marks lisaftoclax as the first Bcl-2 inhibitor to receive conditional approval and marketing authorization for CLL/SLL treatment in China, and the second such inhibitor approved globally. Developed by Ascentage Pharma, lisaftoclax aims to restore the normal apoptosis process in cancer cells by selectively blocking the antiapoptotic protein Bcl-2. The approval is based on positive results from a pivotal registrational Phase II study, highlighting Ascentage Pharma's capabilities in global clinical development and innovation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief on July 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06855","symbol_name":"亞盛醫藥-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nNDLb2Pvrx:1","article_id":"2550612672","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550612672","pubTimestamp":1752137866,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ascentage Pharma Group International has announced that its novel Bcl-2 selective inhibitor, lisaftoclax , has received approval from China's National Medical Products Administration  for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma  who have previously undergone at least one systemic therapy, including Bruton's tyrosine kinase  inhibitors. This marks lisaftoclax as the first Bcl-2 inhibitor to receive conditional approval and marketing authorization for CLL/SLL treatment in China, and the second such inhibitor approved globally. Developed by Ascentage Pharma, lisaftoclax aims to restore the normal apoptosis process in cancer cells by selectively blocking the antiapoptotic protein Bcl-2. The approval is based on positive results from a pivotal registrational Phase II study, highlighting Ascentage Pharma's capabilities in global clinical development and innovation.Disclaimer: This news brief was created by Public Technologies  using genera","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06855":"亚盛医药-B","BK1574":"生物医药B类股","BK1161":"生物科技"},"translate_title":"亚盛医药新型Bcl-2抑制剂Lisaftoclax获中国NMPA批准用于治疗CLL/SLL患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":0.9},"content_text":"Ascentage Pharma's Novel Bcl-2 Inhibitor Lisaftoclax Receives Approval from China's NMPA for Treatment of CLL/SLL Patients\n    \n\nAscentage Pharma Group International has announced that its novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), has received approval from China's National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously undergone at least one systemic therapy, including Bruton's tyrosine kinase $(BTK.AU)$ inhibitors. This marks lisaftoclax as the first Bcl-2 inhibitor to receive conditional approval and marketing authorization for CLL/SLL treatment in China, and the second such inhibitor approved globally. Developed by Ascentage Pharma, lisaftoclax aims to restore the normal apoptosis process in cancer cells by selectively blocking the antiapoptotic protein Bcl-2. The approval is based on positive results from a pivotal registrational Phase II study, highlighting Ascentage Pharma's capabilities in global clinical development and innovation.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief on July 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}